Skip to content
10-Q

Quarterly Report

OnKure Therapeutics, Inc. OKUR

0000950170-24-123233

← back to feed
Filed
Nov 7, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Short Term Investments Q3 2024 · Sep 30, 2024 $15.98M
Short Term Investments Q3 2024 · Dec 31, 2023 $75.33M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $60.69M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $27.63M
Current Liabilities Q3 2024 · Sep 30, 2024 $3.25M
Current Liabilities Q3 2024 · Dec 31, 2023 $18.18M
Total Liabilities Q3 2024 · Sep 30, 2024 $3.63M
Total Liabilities Q3 2024 · Dec 31, 2023 $18.83M
Current Assets Q3 2024 · Sep 30, 2024 $77M
Current Assets Q3 2024 · Dec 31, 2023 $106.62M
Total Assets Q3 2024 · Sep 30, 2024 $77.65M
Total Assets Q3 2024 · Dec 31, 2023 $107.44M
Shares Diluted restated Q3 2024 · Sep 30, 2023 3.38M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 2.97M sh
Capex Q3 2024 · Sep 30, 2023 $196K
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$43.93M
Stockholders Equity Q3 2024 · Sep 30, 2023 $114.94M
Stockholders Equity Q3 2024 · Jun 30, 2023 $132.53M
Stockholders Equity Q3 2024 · Mar 31, 2023 $87.08M
Stockholders Equity Q3 2024 · Dec 31, 2022 $99.97M
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$5.68
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$18.11
Eps Basic restated Q3 2024 · Sep 30, 2023 −$5.68
Eps Basic restated Q3 2024 · Sep 30, 2023 −$18.11
Sga Expense Q3 2024 · Sep 30, 2023 $7.27M
Sga Expense Q3 2024 · Sep 30, 2023 $19.04M
Rd Expense Q3 2024 · Sep 30, 2023 $13.62M
Rd Expense Q3 2024 · Sep 30, 2023 $39.01M
Net Income Q3 2024 · Sep 30, 2023 −$19.2M
Net Income Q3 2024 · Sep 30, 2023 −$53.83M
Net Income Q3 2024 · Jun 30, 2023 −$19.53M
Net Income Q3 2024 · Mar 31, 2023 −$15.11M
Operating Income Q3 2024 · Sep 30, 2023 −$20.89M
Operating Income Q3 2024 · Sep 30, 2023 −$58.05M